<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0000717'>Autism</z:hpo> and <z:hpo ids='HP_0000729'>autism spectrum disorders</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ASDs</z:e>) are <z:hpo ids='HP_0001425'>heterogeneous</z:hpo>, severe neuro-<z:e sem="disease" ids="C0008073" disease_type="Mental or Behavioral Dysfunction" abbrv="">developmental disorders</z:e> with core symptoms of dysfunctions in social interactions and communication skills, restricted interests, repetitive - stereotypic verbal and non-verbal behaviors </plain></SENT>
<SENT sid="1" pm="."><plain>Biomolecular evidence points to complex gene-environmental interactions in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ASDs</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Several biochemical processes are associated with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ASDs</z:e>: <z:mp ids='MP_0003674'>oxidative stress</z:mp> (including endoplasmic reticulum stress), decreased methylation capacity, limited production of <z:chebi fb="0" ids="16856">glutathione</z:chebi>; <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> dysfunction, intestinal dysbiosis, increased toxic metal burden, and various immune abnormalities </plain></SENT>
<SENT sid="3" pm="."><plain>The known immunological disorders include: T-lymphocyte populations and function, gene expression changes in monocytes, several autoimmune-related findings, high levels of N-acetylgalactosaminidase (which precludes macrophage activation), and primary <z:hpo ids='HP_0002721'>immune deficiencies</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>These immunological observations may result in minicolumn structural changes in the brain, as well as, abnormal immune mediation of synaptic functions </plain></SENT>
<SENT sid="5" pm="."><plain>Equally, these <z:hpo ids='HP_0002958'>immune dysregulations</z:hpo> serve as the rationale for immune-directed interventions such as hematopoietic stem cells (<z:chebi fb="15" ids="50443">HSCs</z:chebi>), which are pivotal in controlling <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mp ids='MP_0001845'>inflammation</z:mp> and in the restoration of immunological balance </plain></SENT>
<SENT sid="6" pm="."><plain>These properties make them intriguing potential agents for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ASD</z:e> treatments </plain></SENT>
<SENT sid="7" pm="."><plain>This prospective review will focus on the current state-of-the-art knowledge and challenges intrinsic in the application of <z:chebi fb="15" ids="50443">HSCs</z:chebi> for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ASD</z:e>-related immunological disorders </plain></SENT>
</text></document>